Waquar Ahsan | Drug Discovery and Development | Research Excellence Award

Published on by Top Pharmaceutical

Research Excellence Award: Waquar Ahsan

Waquar Ahsan – Jazan University, College of Pharmacy, Saudi Arabia

Waquar Ahsan
Researcher Waquar Ahsan
Affiliation Jazan University
Country Saudi Arabia
Scopus ID 24605168800
Documents 115
Citations 3,288
h-index 33
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-5987-2933

Waquar Ahsan is a pharmaceutical researcher affiliated with the College of Pharmacy at Jazan University, Saudi Arabia. His academic contributions encompass pharmaceutical chemistry, drug discovery, nanomedicine, formulation development and pharmacological investigations. His research profile reflects interdisciplinary engagement with emerging therapeutic technologies and pharmaceutical innovation. His scholarly record provides a foundation for consideration under the Research Excellence Award at the International Top Pharmaceutical Awards. [1]

1. Abstract

This article presents the academic and research contributions of Waquar Ahsan in pharmaceutical sciences, with particular emphasis on drug discovery and development. His documented publications cover nanostructured drug delivery systems, anticancer formulations, molecular interactions and therapeutic applications of pharmaceutical compounds. These research areas demonstrate an interdisciplinary approach connecting pharmaceutical chemistry, formulation science and biomedical research. His scholarly activities provide relevant evidence for recognition of research contributions and scientific advancement. [2]

2. Keywords

Waquar Ahsan; Research Excellence Award; Drug Discovery and Development; Pharmaceutical Chemistry; Nanomedicine; Drug Delivery Systems; Pharmaceutical Formulation; Anticancer Research; Molecular Docking; Pharmacological Research.

3. Introduction

Drug discovery and development involve interconnected scientific disciplines focused on identifying therapeutic candidates, optimizing formulations and investigating their biological properties. Research in these areas contributes to the development of innovative pharmaceutical approaches and improved drug delivery strategies. Waquar Ahsan’s publication record includes investigations addressing pharmaceutical formulations, natural compounds, nanotechnology-based interventions and potential therapeutic applications, reflecting the multidisciplinary character of contemporary pharmaceutical research. [3]

4. Research Profile

According to his ORCID record, Waquar Ahsan is associated with the College of Pharmacy at Jazan University, Saudi Arabia, as an Associate Professor of Pharmaceutical Chemistry. His registered scholarly activities include journal articles and research contributions across pharmaceutical and biomedical disciplines. His ORCID profile also documents his Scopus Author ID and research outputs, supporting the identification and verification of his academic publications. [1]

5. Research Contributions

Additional contributions concern therapeutic deep eutectic systems and pharmaceutical delivery applications. His collaborative research also addresses natural compounds, molecular docking and pharmacological investigations. Such research themes are relevant to exploring formulation optimization, compound characterization and potential therapeutic mechanisms. They demonstrate the connection between pharmaceutical chemistry and emerging approaches to drug discovery and development. [5]

6. Publications

His documented publications include Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ, published in Nanomedicine (2024), and Development of nanobigel system combining apoptosis-inducing daidzein and flaxseed oil for the synergistic treatment of skin cancer, published in the Journal of Drug Delivery Science and Technology (2024). Both publications address nanotechnology-assisted pharmaceutical formulation research. [3] [4]

7. Research Impact

The research record demonstrates contributions across pharmaceutical chemistry, drug delivery, nanomedicine and therapeutic investigations. His collaborative publications provide scientific perspectives on formulation development and potential applications of pharmaceutical compounds. The reported citation indicators further offer measurable evidence of scholarly visibility. Continued research into advanced delivery platforms and therapeutic candidates may contribute to future developments in pharmaceutical and biomedical sciences. [2] [4]

8. Award Suitability

Waquar Ahsan’s research activities demonstrate relevance to the Research Excellence Award through documented publications, interdisciplinary pharmaceutical investigations and contributions to nanotechnology-assisted drug delivery research. His reported bibliometric indicators provide additional quantitative context for academic evaluation. His research profile aligns with the award’s emphasis on scientific contributions, pharmaceutical innovation and scholarly advancement within drug discovery and development. [1] [2]

9. Conclusion

Waquar Ahsan’s academic profile reflects sustained engagement with pharmaceutical chemistry, nanomedicine and drug discovery research. His documented publications demonstrate collaborative contributions to advanced formulations and potential therapeutic applications. The combination of research outputs, interdisciplinary interests and reported scholarly indicators establishes a relevant academic profile for consideration under the Research Excellence Award presented by the International Top Pharmaceutical Awards.

11. References

  1. Elsevier. (n.d.). Scopus author details: Waquar Ahsan, Author ID 24605168800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=24605168800
  2. Mangla, B., Mittal, P., Kumar, P., Javed, S., Ahsan, W., and Aggarwal, G. (2024). Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ. Nanomedicine.
    DOI: 10.2217/nnm-2023-0260
  3. Mangla, B., Kaur, A., Kumar, P., Javed, S., Ahsan, W., and Popli, H. (2024). Development of nanobigel system combining apoptosis-inducing daidzein and flaxseed oil for the synergistic treatment of skin cancer. Journal of Drug Delivery Science and Technology.
    DOI: 10.1016/j.jddst.2024.105843
  4. Javed, S., Mangla, B., Sultan, M. H., Almoshari, Y., Sivadasan, D., Madkhali, O. A., and Ahsan, W. (2024). Pharmaceutical applications of therapeutic deep eutectic systems (THEDES) in maximising drug delivery. Heliyon.
    DOI: 10.1016/j.heliyon.2024.e29783
  5. Khalid, A., Khan, W., Zia, K., Azizuddin, Ahsan, W., and collaborators. (2023). Natural coumarins from Murraya paniculata as mixed-type inhibitors of cholinesterases: In vitro and in silico investigations. Frontiers in Pharmacology.
    DOI: 10.3389/fphar.2023.1133809

Shamama Javed | Drug Delivery Systems | Pharmaceutical Excellence Award

Published on by Top Pharmaceutical

Pharmaceutical Excellence Award

Shamama Javed – Jazan University, Saudi Arabia

Shamama Javed
Affiliation Jazan University, Faculty of Pharmacy
Country Saudi Arabia
Scopus ID 24921416100
Documents 53
Citations 1,992
h-index 22
Subject Area Drug Delivery Systems
Event International Top Pharmaceutical Awards
ORCID 0000-0003-2145-9956

Shamama Javed is a pharmaceutical researcher affiliated with the Faculty of Pharmacy at Jazan University, Saudi Arabia. Her scholarly work encompasses pharmaceutics, advanced drug delivery, nanotechnology, pharmaceutical formulation, and therapeutic applications of bioactive compounds. Her research profile demonstrates contributions to pharmaceutical sciences through publications addressing formulation development, drug delivery strategies, and emerging biomedical applications. These research areas provide the academic context for her recognition under the Pharmaceutical Excellence Award. [1]

Abstract

Shamama Javed’s research profile reflects academic contributions to contemporary pharmaceutical sciences, particularly drug delivery systems and nanotechnology-based formulations. Her publications explore advanced pharmaceutical carriers, formulation optimization, therapeutic applications of natural compounds, and approaches to improving drug delivery. The documented scholarly record includes research articles and reviews published in international journals. Her research activities demonstrate an interdisciplinary approach connecting pharmaceutics, nanomedicine, and biomedical research. [2]

Keywords

Shamama Javed; Pharmaceutical Excellence Award; Drug Delivery Systems; Pharmaceutics; Nanotechnology; Nanomedicine; Pharmaceutical Formulation; Drug Delivery Research; Nanocarriers; Pharmaceutical Sciences.

Introduction

Pharmaceutical research plays an important role in developing innovative formulations, improving therapeutic delivery, and addressing challenges associated with drug solubility, stability, and bioavailability. Shamama Javed’s scholarly contributions address several of these research priorities through investigations into pharmaceutical carriers, nanostructured formulations, and drug delivery technologies. Her publication record provides evidence of sustained engagement with research topics relevant to pharmaceutical development and therapeutic innovation. [3]

Research Profile

According to her ORCID record, Dr. Javed is an Assistant Professor in Pharmaceutics at the Faculty of Pharmacy, Jazan University, Saudi Arabia. Her registered scholarly activities include publications covering pharmaceutical formulation, nanotechnology, pharmacological applications, and advanced drug delivery approaches. Her ORCID profile records 38 research works, while the supplied Scopus profile reports 53 documents, 1,992 citations, and an h-index of 22. [1] [2]

Research Contributions

Her research contributions encompass the development and evaluation of nanostructured lipid carriers, nanoemulgels, cubosomes, and other pharmaceutical delivery platforms. Her collaborative publication on therapeutic deep eutectic systems examines their pharmaceutical applications in maximizing drug delivery. Additional research addresses specialized formulations and nanotechnology-based approaches relevant to therapeutic development. These subjects demonstrate the breadth of her research engagement in contemporary pharmaceutics. [4] [5]

Publications

Selected publications associated with Javed include Pharmaceutical Applications of Therapeutic Deep Eutectic Systems (2024), Cubosomes in Drug Delivery (2023), Development of Berberine-Loaded Bigel (2024), Design-of-Experiments-Assisted Fabrication of Quercetin-Loaded Nanoemulgel (2022), and Chronicles of Nanoerythrosomes (2021). These works represent research interests spanning formulation science, nanomedicine, pharmaceutical carriers, and therapeutic delivery. Their publication details are accessible through the corresponding DOI records. [4] [5]

Research Impact

The supplied Scopus indicators of 1,992 citations and an h-index of 22 provide quantitative measures of the scholarly visibility of her indexed research. Her publications address pharmaceutical topics with potential relevance to formulation development, therapeutic delivery, and biomedical applications. The combination of research articles and review publications contributes to the academic discussion of emerging pharmaceutical technologies and interdisciplinary approaches. [2]

Award Suitability

Shamama Javed’s documented research activities align with the objectives of the Pharmaceutical Excellence Award presented through the International Top Pharmaceutical Awards. Her work in drug delivery systems, nanotechnology, pharmaceutical formulation, and therapeutic applications demonstrates subject-area relevance. Her indexed publications, documented research contributions, and citation indicators provide a scholarly basis for consideration under this recognition category. [5]

Conclusion

Shamama Javed represents an active contributor to pharmaceutical research, with documented academic work in pharmaceutics, advanced drug delivery, and nanomedicine. Her publication portfolio reflects engagement with contemporary formulation technologies and interdisciplinary therapeutic research. Her academic affiliation and indexed scholarly record establish a relevant foundation for recognition under the Pharmaceutical Excellence Award, acknowledging contributions to the continuing development of pharmaceutical sciences.

References

  1. Elsevier. (n.d.). Scopus author details: Shamama Javed, Author ID 24921416100. Scopus. https://www.scopus.com/authid/detail.uri?authorId=24921416100
  2. Javed, S., et al. (2024). Development and evaluation of berberine-loaded bigel for the treatment of hyperpigmentation on B16F10 melanoma cell line. Nanomedicine. https://doi.org/10.1080/17435889.2024.2370759
  3. Javed, S., et al. (2024). Pharmaceutical applications of therapeutic deep eutectic systems (THEDES) in maximising drug delivery. Heliyon. https://doi.org/10.1016/j.heliyon.2024.e29783
  4. Sivadasan, D., Sultan, M. H., Alqahtani, S. S., & Javed, S. (2023). Cubosomes in drug deliveryโ€”A comprehensive review on its structural components, preparation techniques and therapeutic applications. Biomedicines. https://doi.org/10.3390/biomedicines11041114
  5. Chitkara, A., Mangla, B., Kumar, P., Javed, S., Ahsan, W., & Popli, H. (2022). Design-of-experiments (DoE)-assisted fabrication of quercetin-loaded nanoemulgel and its evaluation against human skin cancer cell lines. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14112517

Marian Sobhy Waheeb Azer | Pharmaceutical Sciences | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Marian Sobhy Waheeb Azer โ€” Misr University for Science & Technology, Egypt

Marian Sobhy Waheeb Azer
Affiliation Misr University for Science & Technology
Country Egypt
Subject Area Pharmaceutical Sciences
Event International Top Pharmaceutical Awards
ORCID 0000-0003-1072-9893

Marian Sobhy Waheeb Azer is a researcher associated with pharmaceutical sciences whose ORCID record lists work on drug delivery, formulation development, and pharmacokinetic evaluation. The documented topics include a lamotrigine self-nanoemulsifying delivery system and a ciclopirox olamine emulgel formulation. These subjects reflect practical research interests in dosage-form design, pharmaceutical characterization, and the investigation of drug delivery performance. This article summarizes the available profile information and its relevance to the Innovative Research Award without assuming unverified bibliometric indicators or award outcomes.[1][2]

Abstract

This profile reviews the pharmaceutical research themes documented in Marian Sobhy Waheeb Azerโ€™s ORCID record. The listed publications concern formulation development and drug delivery, including a solid self-nanoemulsifying system for lamotrigine and a topical emulgel containing ciclopirox olamine. These topics are relevant to pharmaceutical formulation, characterization, and evaluation of drug delivery systems. The available record supports a focused account of these research activities, but does not independently establish citation totals, an h-index, or an official award decision.[1][2]

Keywords

Pharmaceutical sciences; drug delivery systems; lamotrigine; self-nanoemulsifying drug delivery; pharmacokinetics; ciclopirox olamine; emulgel formulation; pharmaceutical characterization; formulation research; innovative research.

Introduction

Pharmaceutical research connects the design of dosage forms with the assessment of their properties and potential performance. Delivery-system development can investigate how formulation components influence drug solubilization, release, and absorption, while topical formulations address the requirements of local administration. Azerโ€™s documented work sits within these broad areas. The available publication metadata provides a basis for describing the research topics, although detailed experimental results should be taken from the original articles rather than inferred from titles alone.[1][2]

Research Profile

The supplied ORCID profile identifies Marian Sobhy Azer and lists two research works. One is a 2020 journal article in Drug Design, Development and Therapy on the development, characterization, and in-vivo pharmacokinetic study of a lamotrigine solid self-nanoemulsifying drug delivery system. The other concerns the development and characterization of ciclopirox olamine emulgel for topical drug delivery, listed as published in 2014. The profile does not provide verified Scopus author metrics in the supplied document.[1][2]

Research Contributions

The lamotrigine study addresses a formulation approach designed to support drug delivery and includes characterization and in-vivo pharmacokinetic evaluation in its stated scope. Such work connects pharmaceutical development with the measurement of drug disposition, although specific outcomes require consultation of the full publication. The topical emulgel work focuses on a formulation containing ciclopirox olamine, illustrating a separate dosage-form application. Together, the listed topics show engagement with both systemic delivery research and topical formulation development.[1][2]

Publications

The ORCID profile lists two publications related to pharmaceutical sciences. One focuses on the development and evaluation of a lamotrigine drug delivery system, while the other examines the formulation and characterization of ciclopirox olamine emulgel for topical drug delivery.[1][2]

Research Impact

The documented subjects are relevant to formulation scientists and pharmaceutical researchers investigating delivery strategies and dosage-form characteristics. However, research impact should be assessed using verified evidence such as citation records, independent adoption, reproducibility, and influence on subsequent work. Citation counts and h-index values are not present in the supplied ORCID document, so no numerical impact claim is made here. Further evaluation can use indexed publication records and the full-text articles.[1][3]

Award Suitability

The listed work provides subject-matter relevance to an Innovative Research Award in pharmaceutical sciences, particularly through formulation development and drug delivery investigations. A fair assessment would examine originality, methodological quality, reproducibility, publication integrity, practical significance, and the candidateโ€™s specific contribution to each study. The information presented here is a profile summary, not confirmation of nomination, selection, or receipt of an award. Final eligibility and recognition must be verified with the award organizer.[4]

Conclusion

Marian Sobhy Waheeb Azerโ€™s supplied ORCID record documents research related to lamotrigine delivery systems and ciclopirox olamine topical formulation. These subjects are pertinent to pharmaceutical formulation and evaluation. The record offers a starting point for academic recognition, while a complete assessment requires the original articles, verified bibliometric data, and evidence of individual research contributions. Readers should consult the linked primary sources for publication details and the official award website for current event information.

References

  1. Azer, M. S. (2020). Development, Characterization, and in-vivo Pharmacokinetic Study of Lamotrigine Solid Self-Nanoemulsifying Drug Delivery System. Drug Design, Development and Therapy. DOI: 10.2147/DDDT.S263898.
  2. Azer, M. S. (2014). Development and Characterization of Ciclopirox Olamine Emulgel for Topical Drug Delivery. Inventi Impact: Pharm Tech. Publication details transcribed from the supplied ORCID profile. https://inventi.in/journal/article/1/7319/Inventi%20Impact:%20Pharm%20Tech/Pharmaceutical
  3. ORCID. (n.d.). Marian Sobhy Azer: Researcher record and works. https://orcid.org/0000-0003-1072-9893.
  4. International Top Pharmaceutical Awards. (n.d.). Official award website. Award eligibility and recognition details should be confirmed with the organizer. https://toppharmaceutical.org/.

Shweta Patel | Women Researcher Award | Pharmaceutical

Published on by Top Pharmaceutical

Women Researcher Award

Shweta Patel โ€” Gokul Global University, India

Shweta Patel
Affiliation Gokul Global University
Country India
Scopus ID 59600471600
Documents 17
Citations 25
h-index 3
Subject Area Pharmaceutical
Event International Top Pharmaceutical Awards
ORCID 0000-0002-8893-3248

Shweta Patel is a researcher associated with Gokul Global University, India, whose documented scholarly record includes pharmaceutical and medicinal chemistry research. Her recent work includes heterocyclic compound synthesis, antimicrobial evaluation, antioxidant studies, and ADME-oriented investigations. The available research record also identifies contributions involving green synthesis and computational assessment of chemical compounds.[1] :contentReference[oaicite:0]{index=0}

Abstract

The research profile of Shweta Patel reflects activity across pharmaceutical chemistry, medicinal chemistry, chemical synthesis, antimicrobial research, and computational drug-development approaches. Available records document studies involving pyran, oxadiazole, thiazolidinone, chromene, quinoline, and related heterocyclic frameworks. Several publications combine synthesis and characterization with biological or ADME-oriented evaluation, providing a multidisciplinary basis for pharmaceutical research.[2]

Keywords

Pharmaceutical Chemistry; Medicinal Chemistry; Drug Discovery; Heterocyclic Chemistry; Antimicrobial Research; Antioxidant Activity; ADME Prediction; Green Synthesis; Chemical Synthesis; Pharmaceutical Innovation.

Introduction

Pharmaceutical research increasingly integrates synthetic chemistry with biological screening and computational approaches to identify compounds with potentially useful pharmacological characteristics. Patel’s documented publications reflect this interdisciplinary pattern, particularly through investigations of heterocyclic derivatives and their antimicrobial or antioxidant properties. The research record also includes studies applying ADME prediction and green synthetic methodologies to pharmaceutical chemistry problems.[3]

Research Profile

The available Scopus-linked record identifies Shweta Patel with Scopus Author ID 59600471600, while the supplied ORCID record identifies 33 works across articles, book chapters, and other research outputs. The documented publication history spans at least 2023โ€“2026 and includes journals such as the Journal of Pharmaceutical Innovation, Russian Journal of General Chemistry, Russian Journal of Organic Chemistry, and related scientific publications.[4]

Research Contributions

A recurring research theme is the design and synthesis of heterocyclic compounds followed by structural characterization and biological evaluation. Recent records include pyrazoleโ€“oxadiazoleโ€“thioacetamide hybrids, 1,8-naphthyridineโ€“thiazolidinone derivatives, chromeneโ€“thiazolidinedione hybrids, and oxadiazole thioacetamide derivatives. These studies demonstrate an emphasis on connecting molecular design with antimicrobial activity and ADME-related assessment.[5]

Publications

The publication portfolio includes recent journal articles and earlier studies in synthetic and pharmaceutical chemistry. Documented examples include work on 2H-pyran derivatives, 1,3,4-oxadiazole derivatives, modified 2-oxochromane compounds, 1,4-dihydropyrano[2,3-c]pyrazoles, and 2-amino-4H-pyrans. The record also contains research on environmental applications of functionalized nanoparticles and pharmaceutical sedation comparisons.[4]

Research Impact

The supplied profile records 17 documents, 25 citations, and an h-index of 3 for the award profile. These metrics provide quantitative indicators of scholarly output and citation activity, although bibliometric values can change as databases are updated. The broader ORCID-linked record indicates additional works and research outputs beyond the selected metrics supplied for this recognition page.[4]

Award Suitability

The documented combination of pharmaceutical chemistry publications, heterocyclic synthesis, antimicrobial evaluation, antioxidant investigations, and ADME-focused research provides a clear scholarly basis for consideration within a pharmaceutical research recognition context. The record contains multiple peer-reviewed journal articles with DOI identifiers, allowing individual publications to be independently located and evaluated. Award consideration should be based on the applicable criteria and verified supporting documentation. [4]

Conclusion

Shweta Patel’s documented research activity encompasses several interconnected areas of pharmaceutical and medicinal chemistry, with particular emphasis on synthetic heterocyclic chemistry and biological evaluation. Her publication record includes recent DOI-indexed studies as well as earlier research on green synthesis and antimicrobial compounds. The available identifiers and publication records provide a basis for further scholarly verification and recognition assessment.

References

 

  1. Elsevier. (n.d.). Scopus author details: Shweta Patel, Author ID 59600471600. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59600471600
  2. Patel, S. A. (2026). Development of a Novel 1,8-Naphthyridineโ€“Thiazolidinone Derivative: Synthesis, Spectral Characterization, Antimicrobial Profiling, and ADME Prediction. Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-026-10426-z
  3. Patel, S. (2026). Structureโ€“Activity Relationship and ADME-Guided Optimization of 4H-Chromene-3-Carbonitrile Derivatives as Promising Antimicrobial Agents. Research Square. https://doi.org/10.21203/rs.3.rs-8718836/v1
  4. Patel, S. (2026). Design and Synthesis of Pyrazoleโ€“Oxadiazoleโ€“Thioacetamide Hybrids with Antimicrobial and Antioxidant Properties. Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-026-10720-w
  5. Patel, S. (2026). Molecular hybridization approach toward quinolineโ€“thiazolidinedione derivatives: synthesis, DPPH radical scavenging activity, and ADME prediction. Journal of the Iranian Chemical Society. https://doi.org/10.1007/s13738-026-03636-2

Mohana Vamsi Nuli | Pharmaceutical Analysis | Best Researcher Award

Published on by Top Pharmaceutical

 

Best Researcher Award

Mohana Vamsi Nuli – Penn Life Sciences

Mohana Vamsi Nuli
Name Mohana Vamsi Nuli
Affiliation Penn Life Sciences
Country United States
Scopus ID 58194986900
Documents 30
Citations 227
h-index 7
Subject Area Pharmaceutical Analysis
Event International Top Pharmaceutical Awards
ORCID 0000-0003-1900-6317

The researcher profile presented here is intended as an academic recognition article for the Best Researcher Award. The award context emphasizes documented research activity, publication quality, subject relevance, methodological contribution, and scholarly visibility. Bibliographic information and publication examples are presented as evidence for evaluating research suitability rather than as an independent assessment of scientific merit.

Abstract

Mohana Vamsi Nuli’s research profile is centered on pharmaceutical analysis and analytical method development, with published work addressing chromatographic techniques, quality-by-design methodology, and sustainable analytical practices. Available bibliographic records identify contributions to HPLC, UHPLC, and LC-MS/MS applications for pharmaceutical and biological samples. [1] [2] These areas are closely aligned with contemporary pharmaceutical research, where reliable analytical procedures are important for characterization, quantification, validation, and quality assessment.

Keywords

Pharmaceutical Analysis; HPLC; UHPLC; LC-MS/MS; Quality by Design; Analytical Chemistry; Green Analytical Chemistry; Method Validation; Pharmaceutical Quality; Chromatography; Drug Analysis; Best Researcher Award.

Introduction

Pharmaceutical analysis provides analytical foundations for drug development, formulation assessment, quality control, and biological measurement. Research in this field increasingly combines chromatographic optimization with experimental design and sustainability considerations. Nuli’s documented publications reflect this direction through studies involving UHPLC, RP-HPLC, LC-MS/MS, and quality-by-design strategies. [2] [3]

Research Profile

The supplied researcher profile records 30 documents, 227 citations, and an h-index of 7, indicating a measurable publication and citation record. The Scopus author record identifies Mohana Vamsi Nuli under Scopus ID 58194986900. His scholarly work includes analytical method development and validation, with research extending to pharmaceutical dosage forms, biological matrices, impurities, and analytical quality assessment.

Research Contributions

A notable theme is the use of design-based analytical development. His 2024 publication on molnupiravir applied Box-Behnken experimental design to UHPLC method development and impurity quantification. [2] Another study applied analytical quality by design to RP-UPLC determination of nivolumab and relatlimab, demonstrating relevance to modern pharmaceutical quality evaluation. [3]

Publications

The publication record includes recent studies in sustainable analytical chemistry and pharmaceutical analysis. Examples include research on ambrisentan-loaded solid lipid nanoparticles, green RP-HPLC determination of phenolic acids, and sustainable UHPLC analysis of antiviral combinations. [1] [4] [5] These publications illustrate a continuing interest in analytical robustness, optimization, and environmentally conscious methodologies.

Research Impact

Research impact can be considered through publication activity, citation indicators, methodological relevance, and contribution to pharmaceutical analytical practice. The supplied profile reports 227 citations and an h-index of 7, while the Scopus record reports 30 documents. These indicators provide quantitative context, although citation metrics should be interpreted alongside publication quality, research originality, methodological rigor, and field-specific standards.

Award Suitability

The documented profile is relevant to a Best Researcher Award in pharmaceutical analysis because it combines sustained publication activity with research addressing contemporary analytical challenges. The portfolio includes quality-by-design methods, chromatographic analysis, pharmaceutical impurity assessment, and green analytical approaches. [1] [3] Final award decisions should additionally consider the complete submission, verified publication record, originality, peer-reviewed impact, and the applicable evaluation criteria of the International Top Pharmaceutical Awards.

Conclusion

Mohana Vamsi Nuli presents a research profile focused on pharmaceutical analysis and analytical method development. His documented work spans chromatographic technologies, quality-by-design approaches, impurity analysis, and sustainable analytical chemistry. The combination of publication activity and reported citation indicators provides a reasonable academic basis for consideration under a Best Researcher Award framework. [2] [4]

References

  1. Singh, M., Tatapudi, H. K., Kanugo, A., Jaini, P. K., & Nuli, M. V. (2026). Application of sustainable QbD based HPLC method for quantification of carboxylic-diphenyl methane drug ambrisentan loaded in solid lipid nanoparticles. Sustainable Chemistry One World, 9, 100158.DOI: https://doi.org/10.1016/j.scowo.2025.100158
  2. Nuli, M. V., Bhikshapathi, D., Garige, A. K., Chandupatla, V., Sunkara, S. L., & Grover, P. (2024). Ultra-high-performance liquid chromatography method development for the quantification of Molnupiravir and its process-related impurities using Box-Behnken experimental design. Separation Science Plus, 7(4).DOI: https://doi.org/10.1002/sscp.202300213
  3. Nuli, M. V., Seemaladinne, R., & Tallam, A. K. (2024). Analytical quality by design (AQbD) based optimization of RP-UPLC method for determination of nivolumab and relatlimab in bulk and pharmaceutical dosage forms. Future Journal of Pharmaceutical Sciences, 10.DOI: https://doi.org/10.1186/s43094-024-00659-5
  4. Nuli, M. V., Jaini, P. K., Jami, D., Tummala, S. R., Chukka, A. K., & Tatapudi, H. K. (2025). Sustainable Quality by Design Approach Based UHPLC Technique for Triple Combination Antiviral Drugs: Appraisal of Green and White Metrics. Separation Science Plus, 8(6).DOI: https://doi.org/10.1002/sscp.70085
  5. Repudi, L., Nuli, M. V., Jaini, P. K., Seemaladinne, R., Chagarlamudi, K., & Gandla, K. (2026). Green and Robust RP-HPLC for Simultaneous Quantification of Gallic, Ferulic, and Caffeic Acids in Human Plasma via Box-Behnken Design-Based Optimization. Drug Metabolism and Bioanalysis.DOI: https://doi.org/10.2174/0118723128455332260605064308

Chao Song | Drug Discovery and Development | Pharmaceutical Excellence Awardย 

Published on by Top Pharmaceutical

Mr. Chao Song | Drug Discovery and Development | Pharmaceutical Excellence Awardย 

Guangxi Traditional Chinese Medical University | China

Mr. Chao Song is a PhD researcher at Guangxi University of Traditional Chinese Medicine, specializing in pharmacology, molecular biology, and translational medicine. He holds advanced academic training in biomedical sciences with a focus on traditional Chinese medicine and intervertebral disc disorders. His professional experience includes active participation in multiple provincial and municipal research projects, demonstrating strong collaborative and leadership capabilities in scientific investigations. His research primarily explores intervertebral disc degeneration, immune regulation, cellular senescence, and multi-omics integration, with contributions spanning network pharmacology, metabolomics, and metagenomics. He has authored numerous high-impact SCI publications, including first-author and corresponding-author works in leading journals, reflecting significant influence in his field. His technical expertise includes advanced experimental and analytical methods such as molecular assays, cell and animal studies, and scientific data visualization. His scholarly contributions have been recognized through competitive research funding, patent development, and consistent publication in high-impact journals, underscoring his growing reputation and commitment to advancing pharmaceutical and biomedical research.

Citation Metrics (Google Scholar)

643
480
320
160
0

643

50

11

Citations

Documents

h-index

Wuting Lu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Wuting Lu | Drug Discovery and Development | Best Researcher Award

Dr. Wuting Lu at Jiangxi Academy of Sciences | China

Dr. Wuting Lu is a dedicated researcher specializing in immunotoxicology, neurobiology, and aquatic toxicology. With a strong academic background and diverse research experience, Dr. Lu has contributed significantly to understanding environmental toxicants and their effects on immunity and neurodevelopment using zebrafish models. He has participated in multiple National Natural Science Foundation of China projects, focusing on mechanisms of high-risk autism genes and their impact on the gut-immune-brain axis. His work has resulted in several high-impact journal publications, advancing knowledge in environmental safety, immunology, and neurobiology. Currently, he serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences.

Publication Profileย 

Orcid

Educationย 

Dr. Wuting Lu completed his Ph.D. in Biology at Nanchang University, where his research explored immunotoxicity and neurodevelopmental effects of environmental pollutants. He earned his M.S. in Neurobiology, also from Nanchang University, focusing on molecular and cellular mechanisms in the nervous system. His academic journey began with a B.S. in Aquaculture at Dalian Ocean University, providing him with a strong foundation in aquatic biology and toxicology. This multidisciplinary training enabled him to integrate environmental science, immunology, and neuroscience into his research, developing expertise in both experimental techniques and advanced molecular analysis approaches for investigating complex biological interactions.

Experienceย 

Dr. Wuting Lu professional career includes roles in academic research and laboratory management. He currently serves as Assistant Research Fellow at the Institute of Microbiology, Jiangxi Academy of Sciences, where he investigates immunotoxicity and neurotoxicity mechanisms. Before this, he worked as a Laboratory Technician at Jinggangshan University, gaining hands-on experience in molecular biology, immunology, and laboratory safety management. He has actively participated in several National Natural Science Foundation of China projects, contributing to studies on autism gene regulation, microglial activation, and the gut-immune-brain axis. His multidisciplinary experience spans aquatic toxicology, neurobiology, immunology, and transcriptomic analysis, bridging fundamental research with environmental health concerns.

Awards and Honorsย 

Dr. Wuting Lu has received recognition for his research contributions through participation in multiple National Natural Science Foundation of China projects, including studies on the high-risk autism gene CHD8 and its effects on microglial activation and the gut-immune-brain axis. His publications in leading journals, such as Fish & Shellfish Immunology and Ecotoxicology and Environmental Safety, highlight his impactful work on immunotoxicity, neurotoxicity, and antioxidant mechanisms in aquatic organisms. While early in his independent research career, his achievements demonstrate excellence in experimental design, molecular analysis, and scientific communication, positioning him as a promising researcher in environmental health and neuroimmunology fields.

Research Focusย 

Dr. Wuting Lu research focuses on immunotoxicity, neurotoxicity, and environmental safety, particularly investigating the effects of environmental toxicants on immune and nervous system development using zebrafish as a model organism. He explores molecular mechanisms underlying pollutant-induced oxidative stress, immune dysregulation, and neurodevelopmental impairments. Additionally, he studies the regulatory roles of genes, such as CHD8, in microglial activation and the gut-immune-brain axis, linking environmental exposures to autism spectrum disorders. His work integrates toxicology, transcriptomics, and neuroimmunology to elucidate pathways of toxicity, identify potential biomarkers, and provide insights into environmental risk assessment, contributing to public health and ecological sustainability research.

Publication Top Notes

Immunotoxicity and neurotoxicity induced by natural borneol and synthetic borneol in zebrafish (Danio rerio)

Immunotoxicity and transcriptome analysis of zebrafish embryos exposure to Nitazoxanide

Conclusion

Overall, Dr. Wuting Lu exhibits a strong research trajectory with impactful publications, interdisciplinary expertise, and contributions to nationally funded projects. His work in environmental toxicology, neurobiology, and molecular mechanisms aligns well with the objectives of the Best Researcher Award. With continued focus on independent project leadership and global collaboration, Dr. Lu has the potential not only to be a strong award candidate but also to emerge as a leading researcher in his field.

Josรฉ Leite | Drug Discovery and Development | Innovator in Pharmaceutical Research Award

Published on by Top Pharmaceutical

Josรฉ Leite | Drug Discovery and Development | Innovator in Pharmaceutical Research Award

Dr. Josรฉ Leite, Universidade de Brasรญlia – UnB, Brazil

Dr. Josรฉ Roberto Leite is a Brazilian biochemist and molecular biologist with a PhD from the University of Brasรญlia ๐Ÿ‡ง๐Ÿ‡ท and postdoctoral training at EMBRAPA and the University of Porto ๐Ÿ‡ต๐Ÿ‡น. He is an Associate Professor at UnBโ€™s Faculty of Medicine and Visiting Researcher at i3S. ๐Ÿงช As co-founder of People&Science, he works on biotechnology, nanobiotech, and bioactive peptides for health and environment ๐ŸŒฟ. With 200+ international publications ๐Ÿ“š, patents under development ๐Ÿ’ก, and global collaborations ๐ŸŒ, he bridges biodiversity and innovation. Dr. Leite also serves as Associate Editor of the Journal of Global Innovation.

Publication Profile

Google Scholar

Education

Dr. Josรฉ Roberto Leite earned his PhD in Biological Sciences (Biochemistry/Molecular Biology) from the University of Brasรญlia ๐Ÿ‡ง๐Ÿ‡ท and completed postdoctoral training at EMBRAPA and the University of Porto (REQUIMTE) ๐Ÿ‡ต๐Ÿ‡น. He serves as an Associate Professor at UnB’s Faculty of Medicine and is a Visiting Researcher at i3S ๐Ÿงฌ. He coordinated graduate programs at UFPI and UnB and founded the Biotec/UFPI research group ๐Ÿง‘โ€๐Ÿ”ฌ. As co-founder of People&Science, he leads cutting-edge work in biotechnology, nanobiotechnology, and bioprospecting for health and the environment ๐ŸŒฑ. He is also Associate Editor of the Journal of Global Innovation ๐Ÿ“˜ and promotes international collaboration.

Professional Memberships

Dr. Josรฉ Roberto Leite is actively engaged in Brazil’s leading scientific communities and holds esteemed memberships in the Brazilian Society for Biochemistry and Molecular Biology ๐Ÿงช and the Brazilian Society of Biotechnology ๐Ÿงฌ, reflecting his deep commitment to advancing life sciences and innovation. In addition, he plays a key editorial role ๐Ÿ“– in the Journal of Global Innovation (JGI), contributing to the dissemination of cutting-edge research and fostering interdisciplinary collaboration ๐ŸŒ. His involvement in these professional circles underscores his dedication to scientific excellence, knowledge sharing, and the promotion of impactful biotechnology and molecular biology initiatives across Brazil and beyond.

Research Focus

Dr. Josรฉ Roberto Leite focuses on cutting-edge research in biotechnology, nanobiotechnology, and natural product-based drug discovery ๐ŸŒฑ. His work spans the development of bioactive peptides ๐Ÿงฌ, antimicrobial and anticancer compounds ๐Ÿ’Š, and innovative drug delivery systems ๐Ÿš€. He explores biodiversity to identify novel molecules from amphibians ๐Ÿธ, plants ๐ŸŒฟ, and marine life ๐ŸŒŠ for therapeutic and diagnostic applications. Dr. Leite also contributes to the advancement of biosensors, nutraceuticals, and functional biomaterials. His interdisciplinary research bridges biochemistry, molecular biology, and pharmacology, driving translational science for global health and environmental impact.

Publication Top Notes

Dermaseptins from Phyllomedusa oreades andPhyllomedusa distincta: ANTI-TRYPANOSOMA CRUZI ACTIVITY WITHOUT CYTOTOXICITY TO MAMMALIAN CELLS

Phylloseptins: a novel class of anti-bacterial and anti-protozoan peptides from the Phyllomedusa genus

Transtornos de ansiedade e exercรญcio fรญsico

Identification of a cowpea ฮณโ€thionin with bactericidal activity

Antimicrobial activity of the bufadienolides marinobufagin and telocinobufagin isolated as major components from skin secretion of the toad Bufo rubescens

Medical students, spirituality and religiosity-results from the multicenter study SBRAME

Anti-inflammatory and Antinociceptive Activity of Epiisopiloturine, an Imidazole Alkaloid Isolated fromย Pilocarpus microphyllus

Novel dermaseptins from Phyllomedusa hypochondrialis (Amphibia)

Development and antibacterial activity of cashew gum-based silver nanoparticles

Antinociceptive activity of the monoterpeneย ฮฑ-phellandrene in rodents: possible mechanisms of action

The NMR-derived solution structure of a new cationic antimicrobial peptide from the skin secretion of the anuran Hyla punctata

Antidiarrheal activity of cashew GUM, a complex heteropolysaccharide extracted from exudate of Anacardium occidentale L. in rodents

Yu Liu | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Yu Liu | Drug Discovery and Development | Best Researcher Award

Mr. Yu Liu, China Institute of Pharmaceutical Industry Co., Ltd, China

Dr. Liu Yu (b. January 11, 1981, Hengyang, Hunan) is a distinguished researcher and doctoral supervisor specializing in medicinal chemistry. He earned his Ph.D. from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2011). Currently, he serves as Deputy Director at the China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center. He is also a standing committee member of the Health Economics Theory and Policy Committee. Dr. Liu plays a pivotal role in pharmaceutical research and technology transfer in China.

Publication Profile

Scopus

Education

Mr. Yu Liu pursued his education in Medicinal Chemistry ๐Ÿงช at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences ๐ŸŽ“. He was enrolled as a full-time student from September 2008 to July 2011 ๐Ÿ“…. During this period, he dedicated himself to advanced research in the field, ultimately earning a Doctorate degree ๐ŸŽ–๏ธ. His studies focused on the development of medicinal compounds and pharmaceutical innovations, contributing to the field of drug discovery and development ๐Ÿ’Š. With a strong academic foundation, Mr. Liu gained expertise in chemical synthesis and pharmacology, preparing him for a successful career in medicinal sciences ๐Ÿ”ฌ.

Professional Leadership

Mr. Yu Liu serves as the Deputy Director ๐Ÿ›๏ธ at both the Technology Transfer Center, China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center ๐Ÿ”ฌ. In these roles, he plays a pivotal part in advancing pharmaceutical and biotechnology research ๐Ÿ’Š. His leadership drives innovation in drug development and synthesis, ensuring progress in the field of medicinal chemistry ๐Ÿงช. With his extensive expertise, Mr. Liu significantly contributes to technology transfer, regulatory advancements, and pharmaceutical innovation, reinforcing his influence in the global healthcare industry ๐ŸŒ.

Experience

Mr. Yu Liu is an esteemed member of high-level academic committees ๐Ÿ›๏ธ, including the Standing Committee of the Health Economics Theory and Policy Professional Committee under the Chinese Association of Health Economics ๐Ÿ“Š. His active participation in these organizations reflects his dedication to bridging scientific innovation and economic policy in healthcare ๐Ÿ’ก๐Ÿ’ฐ. By contributing to policy development and strategic decision-making, he plays a crucial role in shaping the future of health economics and pharmaceutical advancements ๐Ÿ’Š. His interdisciplinary expertise ensures a significant impact on both scientific research and economic frameworks, fostering innovation in healthcare systems ๐ŸŒ.

Research Focus

Yu Liuโ€™s research focuses on analytical chemistry, particularly in pharmaceutical analysis. His expertise lies in the development and validation of advanced chromatographic techniques, such as GC (Gas Chromatography) and HPLC-RID (High-Performance Liquid Chromatography with Refractive Index Detection). His work involves identifying and quantifying related substances in pharmaceutical compounds, including novel impurities in tetrabenazine. His contributions ensure drug purity, safety, and efficacy, making a significant impact on quality control and regulatory compliance in the pharmaceutical industry. His research bridges analytical chemistry and pharmaceutical sciences, advancing drug formulation and safety.

Publication Top Notes

GC and HPLC-RID method development and validation for the determination of twelve related substances, including several novel compounds in tetrabenazine

Roxana Matran | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Roxana Matran | Pharmacology | Best Researcher Award

Assist Prof Dr Roxana Matran, UMF “Carol Davila”, Romania

Dr. Roxana Matran is a distinguished pediatric gastroenterologist and academic with a Ph.D. from Carol Davila University of Medicine and Pharmacy (2017) ๐ŸŽ“. An Assistant Professor at the same university since 2019, she excels in teaching and research on pediatric pulmonology and gastroenterology. Her clinical expertise at “Grigore Alexandrescu” Emergency Hospital for Children includes contributions to groundbreaking clinical trials on inflammatory bowel diseases ๐Ÿฅ๐Ÿ”ฌ. A dedicated volunteer with MD Caravana cu Medici ๐Ÿค, she brings healthcare to underserved communities. Dr. Matranโ€™s active membership in ESPGHAN and advisory roles showcase her impactful influence in public health policy ๐ŸŒโœจ.

Publication Profile

orcid

Educational Backgrounds

Assist. Prof. Dr. Roxana Matran embarked on her academic journey at the prestigious Central School in Bucharest, where she specialized in Mathematics-Informatics with bilingual French instruction (๐Ÿ“˜โœ๏ธ). She continued her education at “Carol Davila” University of Medicine and Pharmacy, earning a Bachelor’s Degree in 2009 (๐ŸŽ“๐Ÿฉบ). Driven by her passion for medicine, she pursued a Ph.D. at the same university, completing her thesis on factors contributing to pulmonary disease in cystic fibrosis between 2013 and 2017 (๐Ÿ“„๐Ÿซ). Her dedication and expertise in the medical field have solidified her reputation as a leading academic and researcher in Bucharest (๐ŸŒŸ๐Ÿฅ).

Work Experiance

Assist. Prof. Dr. Roxana Matran is a distinguished pediatric gastroenterologist and academic based in Bucharest. She serves as a member of the Advisory Committee on Post-Vaccination Adverse Reactions, analyzing vaccine-related health concerns (๐Ÿ’‰๐Ÿ“Š). She is also a sub-investigator in pivotal clinical trials, including studies on Vedolizumab and Adalimumab for pediatric Crohnโ€™s disease and ulcerative colitis (๐Ÿ”ฌ๐Ÿ“‘). Dr. Matran volunteers with Caravana cu Medici, offering medical consultations in underserved Romanian villages (๐Ÿš‘๐Ÿค). As an Assistant Professor at “Carol Davila” University, she teaches fifth-year medical students and conducts extensive research (๐Ÿ“š๐Ÿ‘ฉโ€๐Ÿ”ฌ). Her work at “Grigore Alexandrescu” Emergency Hospital focuses on consultations, rounds, and clinical studies (๐Ÿฅ๐Ÿ‘ถ).

Membership

Assist. Prof. Dr. Roxana Matran is an active member of esteemed professional organizations in her field. Since June 2019, she has been a Full Member of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN), contributing to advancements in pediatric healthcare across Europe (๐ŸŒ๐Ÿ‘ถ๐Ÿฉบ). Additionally, she has been a dedicated member of the Romanian Society of Pediatrics since July 2016, working to promote excellence in pediatric medicine and research in her home country (๐Ÿ‡ท๐Ÿ‡ด๐Ÿ“š๐Ÿ’‰). Her involvement in these societies underscores her commitment to improving children’s health and staying at the forefront of medical advancements (๐ŸŒŸ๐Ÿ”ฌ).

Conference and Seminars

Assist. Prof. Dr. Roxana Matran has an extensive track record of participation in prestigious medical events and specialized training programs worldwide. In 2024, she is set to attend the 5th Liver Transplant School in Brussels (25โ€“28 September) and the ESPGHAN Mastercourse in Parenteral Nutrition in Linz, Austria (4โ€“6 March). Her prior engagements include the ESPGHAN IBD Masterclass in Helsinki, Finland (2022) and the International Symposium on Pediatric Inflammatory Bowel Disease in Edinburgh, Scotland (2022). Over the years, she has honed her expertise in pediatric gastroenterology, nutrition, and pulmonology, attending courses in Italy ๐Ÿ‡ฎ๐Ÿ‡น, Austria ๐Ÿ‡ฆ๐Ÿ‡น, France ๐Ÿ‡ซ๐Ÿ‡ท, and Greece ๐Ÿ‡ฌ๐Ÿ‡ท, and even completing a post-graduate program online ๐ŸŒ.

Community Impact

Assist. Prof. Dr. Roxana Matran is deeply committed to serving underserved communities, demonstrating her passion for equitable healthcare access. She actively volunteers with MD Caravana cu Medici, a noble initiative providing essential medical consultations in impoverished Romanian villages ๐Ÿก. Through this work, Dr. Matran brings her expertise in pediatric gastroenterology and nutrition to those who need it most, offering care, guidance, and hope ๐ŸŒŸ. Her dedication to improving public health goes beyond the clinic, reflecting a strong sense of compassion and responsibility toward marginalized populations ๐Ÿค. Dr. Matranโ€™s efforts exemplify the true spirit of community service and medical care โค๏ธ.

Clinical Expertise

Assist. Prof. Dr. Roxana Matran has made significant contributions to pediatric gastroenterology through her clinical practice, research, and involvement in clinical trials. As a pediatric gastroenterologist at “Grigore Alexandrescu” Emergency Hospital for Children ๐Ÿฅ, she seamlessly combines patient care with groundbreaking research. Dr. Matran has actively contributed as a subinvestigator for leading pharmaceutical companies, including Takeda Pharmaceuticals (VedolizumabSC-3003) and AbbVie (Adalimumab), advancing therapies for pediatric inflammatory bowel disease ๐Ÿ”ฌ. She also researches post-vaccination adverse reactions as a member of the Advisory Committee at the Ministry of Health, ensuring better health outcomes for children globally ๐Ÿ’‰.

Research Focus

Dr. Roxana Elena Smฤƒdeanu’s research focus primarily revolves around pediatric health, with a special emphasis on diagnosing and managing complex diseases such as cystic fibrosis, intestinal tuberculosis, and respiratory conditions in children. Her work includes exploring microbiota’s role in functional abdominal pain disorders, respiratory symptomatology associated with COVID-19 in pediatric patients, and rare genetic syndromes like Menke-Hennekam syndrome. Additionally, her research delves into diagnostic methods like sweat conductivity in cystic fibrosis. This body of work aligns with clinical and laboratory research aimed at improving pediatric healthcare and diagnostics. ๐Ÿง‘โ€๐Ÿ”ฌ๐Ÿฉบ๐Ÿ‘ถ

Publication Top Notes

Anti-Tumor Necrosis Factor-ฮฑ Use in Pediatric Inflammatory Bowel Diseaseโ€”Reports from a Romanian Center

Food Related Quality of Life in Children with Chronic Gastrointestinal Disorders: Comparative Study Between Inflammatory Bowel Disease and Celiac Diseaseโ€”Reports from a Romanian Center

Anti TNF-a Use in Pediatric Inflammatory Bowel Disease โ€“ Reports from a Romanian Center

Quality of Life of Pediatric Patients with Chronic Intestinal, Liver, and Pancreatic Diseases During the COVID-19 Pandemic

Menkeโ€“Hennekam Syndrome: A Literature Review and a New Case Report